Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATR12-351 in Adults With Netherton Syndrome
NCT06137157Phase 1Completed
- Sponsor
- Azitra, Inc.
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATR12-351 in Netherton syndrome (NS), sponsored by Azitra, Inc. Primary endpoint: Adverse Events at 84 days. Started Jun 2024; status: completed.
02
Drugs
ATR12-351
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT06137157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137157.